Soleno Therapeutics Under Investigation
Los Angeles-based Soleno Therapeutics, Inc. (NASDAQ: SLNO) has recently come under scrutiny as the Portnoy Law Firm launches an investigation into potential securities fraud. This development has captured the attention of investors eager to safeguard their interests and understand the implications of this situation.
What Does the Investigation Mean?
The Portnoy Law Firm is urging Soleno investors who might have been affected by these events to reach out and explore their options. Investors can discuss their legal rights with attorney Lesley F. Portnoy, who is committed to helping those who may have suffered financial losses.
Recent Developments at Soleno Therapeutics
Earlier this year, Soleno announced a significant milestone when the U.S. Food and Drug Administration approved their medication, VYKAT XR. This drug is an important development for patients suffering from hyperphagia linked to Prader-Willi syndrome. However, amid these positive advancements, the company faced challenges affecting its stock performance.
The Impact of Short Seller Reports
During a recent earnings call, CEO Anish Bhatnagar revealed that Soleno encountered obstacles due to a short seller report that surfaced unexpectedly. This report has derailed the company's momentum, leading to increased discontinuation rates for VYKAT XR and a notable decline in share price.
Understanding the Stock Performance
Post-announcement of adverse effects associated with VYKAT XR and the fallout from the short seller report, Soleno's stock price plummeted by an alarming 26%. This trend raises essential questions for shareholders about the sustainability of the company's growth and strategic direction moving forward.
Investor Rights and Legal Options
For shareholders concerned about their investments, understanding one's rights is critical. The Portnoy Law Firm specializes in helping investors pursue claims resulting from corporate malpractice, emphasizing that prior successes don’t guarantee similar future results.
Potential for Recovery
Investors looking to recover losses from their engagement with Soleno Therapeutics can access a complimentary case evaluation through the Portnoy Law Firm. This proactive approach can be beneficial for those impacted by the recent events surrounding the company.
Contact Information for Interested Investors
Lesley F. Portnoy offers his expertise and guidance to anyone seeking clarity or wishing to participate in the ongoing investigation. Investors can reach Liz's office by phone or via e-mail to initiate a conversation regarding their financial options.
Frequently Asked Questions
What is the investigation about?
The investigation concerns potential securities fraud involving Soleno Therapeutics, as initiated by the Portnoy Law Firm.
How can I know if I am affected?
If you are a shareholder of Soleno Therapeutics, consider contacting the Portnoy Law Firm to determine your rights and next steps.
What are VYKAT XR's approved uses?
VYKAT XR is approved for managing hyperphagia in individuals aged four and older with Prader-Willi syndrome.
Who represents investors in this matter?
The Portnoy Law Firm, led by attorney Lesley F. Portnoy, represents investors seeking to address their concerns regarding Soleno Therapeutics.
What should I do if I want to take action?
Interested investors should reach out to the Portnoy Law Firm for a complimentary case assessment and guidance on potential claims.
